Back to News Items

November 2012: New Article - Regorafenib Approved to Treat Metastatic Colorectal Cancer

Main Bullet Points:

  • On May 23, 2012 Bayer HealthCare announced their submission for approval of a potential blockbuster cancer drug- Regorafenib.
  • On September 27, 2012 the FDA approved Regorafenib, as the brand name Stivarga, to treat metastatic colorectal cancer
  • On October 29, 2012 Bayer received a priority review by the FDA for the use of Stivarga tablets to treat patients with gastrointestinal stromal tumors
  • Sales of Stivarga are estimated to be over 1.25 billion a year
  • Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in the United States for men and women
  • 29 percent of the patients who received Regorafenib in the Phase lll CORRECT trial had an increased survival rate



Dun and Bradstreet